Related Experiment Videos

Antimicrobial treatment of Flavobacterium meningosepticum infection

Insights

A six-month-old infant recovered from Flavobacterium meningosepticum meningitis and septicemia with cotrimoxazole. Disc diffusion testing for Flavobacterium susceptibility requires Minimum Inhibitory Concentration (MIC) determination for accuracy.

Area of Science:

  • Medical microbiology
  • Infectious diseases
  • Pediatric infectious diseases

Background:

  • Flavobacterium meningosepticum is a rare cause of meningitis and septicemia, particularly in neonates and infants.
  • Antimicrobial resistance in Flavobacterium species poses a significant challenge for effective treatment.

Observation:

  • A six-month-old boy developed severe septicemia and meningitis caused by Flavobacterium meningosepticum type A.
  • Initial treatment with amikacin, chloramphenicol, and sulfonamides, based on disc diffusion susceptibility, proved ineffective.

Findings:

  • Intravenous cotrimoxazole therapy resulted in complete recovery for the patient.
  • Environmental strains of Flavobacterium, including type B, were also identified.
  • Disc diffusion results for chloramphenicol, sulfonamides, and rifampicin did not correlate with Minimum Inhibitory Concentration (MIC) values.
  • All tested Flavobacterium strains showed susceptibility to amikacin, erythromycin, clindamycin, and trimethoprim via both disc diffusion and MIC methods.

Implications:

  • Cotrimoxazole is an effective treatment option for Flavobacterium meningosepticum infections.
  • The disc diffusion method alone is insufficient for determining Flavobacterium antimicrobial susceptibility.
  • Minimum Inhibitory Concentration (MIC) testing should supplement disc diffusion for accurate susceptibility profiling of Flavobacterium species to guide therapy.

Related Concept Videos